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Abstract: Parapneumonic effusion or pleural empyema (PPE/PE) is a frequent complication of
community-acquired pneumonia (CAP) in children. Different management approaches exist for this
condition. We evaluated a 14-day treatment with amoxicillin (AMX) with/without clavulanic acid
(AMC) confirmed or modified by microbiological findings from pleural tap. Children ≤16 years
of age with radiologically diagnosed PPE/PE and initial diagnostic pleural tap were included at
University Children’s Hospital Zurich from 2001–2015. AMX/AMC was given for 14 days and
rationalized according to microbiological pleural tap results. Clinical and radiological follow-up was
scheduled until six months or full recovery. In 114 of 147 (78%) children with PPE/PE a pathogen
was identified by culture, polymerase chain reaction (PCR), and/or antigen testing. Streptococcus
pneumoniae was detected in 90 (79%), S. pyogenes in 13 (11%), and Staphylococcus aureus in seven cases
(6%), all but two cultured pathogens (96%) were sensitive to AMX/AMC. One-hundred two of 147
(69%) patients received treatment with AMX/AMC for 14 days. They recovered more rapidly than
patients with a different management (p = 0.026). Of 139 children with follow-up, 134 (96%) patients
fully recovered. In conclusion, 14-day AMX/AMC treatment confirmed and rarely modified by
microbiological findings from pleural tap resulted in full recovery in >95% of children with PPE/PE.
Keywords: antibiotics; community-acquired pneumonia; chest tube; drainage; fibrinolysis;
parapneumonic effusion; pleural draining catheter; pleural tap; Streptococcus pneumoniae; thoracocentesis;
thoracotomy; video-assisted thoracic surgery
1. Introduction
Parapneumonic effusion or pleural empyema (PPE/PE) develop in about 40% of children with
community-acquired pneumonia (CAP) requiring hospitalization [1]. The incidence of PPE/PE in
children has increased worldwide in recent decades (5.5 per 100,000 in the U.S. in 2006) [2–4]. PPE/PE
is clinically suspected in children with CAP that show persisting fever and lack of improvement
48–72 h after initiation of antibiotic treatment [5]. Sampling of pleural fluid in PPE/PE patients by
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simple pleural tap provides both diagnostic and therapeutic benefit [5]. Microbiologic workup from
pleural fluid or blood in children most frequently reveals Streptococcus pneumoniae as the etiologic agent,
even after the introduction of the pneumococcal conjugate vaccines (PCVs) [2–4,6,7]. The dynamic
evolution of the inflammatory process in PPE/PE is divided into three stages, characterized as follows:
stage 1, free-floating fluid, stage 2, fluid loculated by fibrous septations, and stage 3, consolidation
(empyema) [8]. This staging and the size of the effusion influence the management of PPE/PE [5]. Yet,
the optimal management of PPE/PE is controversial [9]. The applied therapeutic strategies include
administration of antibiotics alone (i.e., amoxicillin (AMX) with/without clavulanic acid (AMC)) or
combined with interventions, such as pleural tap, pleural draining catheter, fibrinolysis, video-assisted
thoracoscopic surgery (VATS), or thoracotomy [1,5,10,11]. Currently, not only the indication but also
the impact of these interventions on duration of hospitalization and outcome are controversially
discussed [1,9–13], and its clinical application often follows rather in-house experience-based protocols
than evidence.
Here, we present a 15-year single-center cohort study of children with PPE/PE by implementing a
management algorithm including diagnostic pleural tap and a 14-day course of empirical antibiotic
treatment. We hypothesized that these patients recover following a 14-day course of AMX/AMC
treatment confirmed or modified by microbiological findings from pleural tap. We further compared
the outcome for PPE/PE patients managed without surgical interventions (i.e., only diagnostic pleural
tap) or with surgical interventions (e.g., pleural draining catheter and VATS).
2. Experimental Section
2.1. Ethics Statement
Ethical approval for this study was granted by the ethics committee of Canton Zurich, Switzerland
(protocol no. 2016-01331; approved: 20 September 2016).
2.2. Patients
Children ≤16 years of age with radiologically confirmed PPE/PE that underwent a diagnostic
pleural tap at University Children’s Hospital Zurich between January 2001 and December 2015
were included in this retrospective analysis. Excluded were children with underlying diseases and
immunosuppression. Patients were treated according to a defined management algorithm including
empirical antibiotic treatment given for 14 days and rationalized according to microbiological findings
from initial pleural tap. The 14-day course of antibiotic treatment was irrespective of pretreatment
duration and regimen. Indications for surgical interventions included high grade or continuing
respiratory compromise, seropneumothorax, and/or large effusions with mediastinal shift [5]. Surgical
interventions were defined as invasive procedures such as chest tube drainage± intrapleural fibrinolytic
therapy, VATS, and thoracotomy. The choice of the surgical intervention was made interdisciplinary
by responsible surgeons and pediatricians. Clinical and radiological follow-up was scheduled up to
6 months or until full recovery.
2.3. Data Collection
Clinical and radiological data were collected at inclusion and at 1-, 3-, and/or 6-month follow-ups.
Biological samples (blood and pleural fluid) were collected at inclusion.
2.4. Imaging
Images were judged by a radiologist during routine radiological assessment. These findings and
the corresponding images were reviewed by two of the authors, who were blinded to details of patient
histories. The images were graded (radiograph) and classified (ultrasound) as follows:
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2.4.1. Quantification (Grade 1–3)
The size of effusion in chest radiograph was assessed according to Bradley et al. [5]: grade 1,
small (opacifies less than one-fourth of hemithorax); grade 2, moderate (opacifies less than half of the
hemithorax); and grade 3, large (opacifies more than half of the hemithorax).
2.4.2. Classification (Stage 1–3)
Sonographic staging was performed according to Kim et al. [8]: stage 1, exudative (free-floating
fluid without loculations or consolidations); stage 2, fibrino-purulent (fluid loculated by fibrous
septations); and stage 3, organized (echogenic, solid-appearing pleural plaque of >1/3 of PPE/PE with
or without some loculation of fluid).
2.5. Microbiological Analyses
2.5.1. Pleural Fluid
Gram stain and conventional bacterial cultures for aerobic an anaerobic organisms were performed
on all pleural fluid specimens [14]. Antigen testing or nucleic acid amplification through polymerase
chain reaction (PCR) was primarily used on culture-negative pleural fluid specimens to increase
the detection of pathogens in pleural fluid. Antigen testing for S. pneumoniae and S. pyogenes was
performed with commercially available tests (Pneumoslide test (BD Diagnostics, Sparks Glencoe, MD,
USA) and Pastorex Strep (Bio-Rad Laboratories Inc., Marne-La-Coquette, France)). Specific PCRs for
S. pneumoniae and pneumococcal serotypes, as well as the broad-range PCR were used as previously
described [15–17].
2.5.2. Blood Culture
Bacterial blood cultures for aerobic and anaerobic organism were performed on all patients with
PPE/PE as described previously [17].
2.6. Follow-up and Outcome
Outcome parameters were length of hospital stay (LOS) and complete clinical and radiological
recovery (i.e., good outcome). LOS was defined as time between first radiological proof of PPE/PE
(time point of inclusion, day 0) and day of hospital discharge. Poor outcome was defined as no
clinical recovery and/or abnormal chest radiograph according to the British Thoracic Society (BTS)
guidelines [1,11].
2.7. Statistical Analysis
Categorical variables were compared by using χ2 or Fisher’s exact analyses. Continuous variables
were compared by using Wilcoxon rank-sum (Mann-Whitney U) analysis. The log-rank test was used
to compare the time to outcome. All reported p values are 2-tailed with significance at <0.05. Analyses
were performed using the R software environment (version 3.4.0, R Core Team, Vienna, Austria) [18].
3. Results
During the 15-year study period, 147 children with radiologically confirmed PPE/PE who
underwent a diagnostic pleural tap were included (Figure 1). Numbers of PPE/PE cases within
5-year-intervals were 24 (16%), 60 (41%), and 63 (43%) from 2001–2005, 2006–2010, and 2011–2015,
respectively. Seventy-three (50%) were male and the median age was four years (interquartile range
(IQR) 3–6 years). At admission, 80 (54%) children presented with PPE/PE (primary PPE/PE) and
67 children (46%) with CAP and a subsequent pleural effusion (secondary PPE/PE). The median time
between onset of initial symptoms and diagnosis of PPE/PE was five days (IQR 3–9 days) for children
with primary PPE/PE and nine days (IQR 7–11 days) for children with secondary PPE/PE (p < 0.001).
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Baseline characteristics of included PPE/PE patients are shown in Table 1, including comparison
between patients managed with pleural tap alone and with surgical interventions.
Figure 1. Study profile. AMC, amoxicillin-clavulanate; AMX, amoxicillin; PE, pleural empyema; PPE,
parapneumonic effusion; CT, computed tomography; CXR, chest radiograph.
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Table 1. Baseline characteristics of the 147 included children with parapneumonic effusion or pleural
empyema (PPE/PE).
Baseline Characteristics
Total Number
of PPE/PE
Patients
PPE/PE Patients
Without Surgical
Intervention
PPE/PE Patients
with Surgical
Intervention OR (95% CI)
p Value
(n = 147) (n = 89, 61%) (n = 58, 39%)
Demographic characteristics
Sex (male), n (%) 73 (50) 48 (54) 25 (43) 1.5 (0.8–3.2) 0.238
Age (years), median (IQR) 4 (3–6) 4 (3–7) 4 (2–5) 0.098
Clinical characteristics
Duration of prodromal fever and/or respiratory symptoms
(days), median (IQR) 7 (4–10) 7 (5–11) 6 (4–9) 0.060
Diagnosis of pneumonia prior to diagnosis of PPE/PE, n (%) 67 (46) 49 (55) 18 (31) 2.7 (1.3–5.8) 0.007
Antibiotics prior to diagnosis of PPE/PE, n (%) 110 (75) 72 (81) 38 (66) 2.2 (1.0–5.1) 0.051
Duration from start antibiotics to diagnosis of PPE/PE (days),
median (IQR) 3 (1–5) 4 (2–6) 2 (0–4) <0.001
Symptoms at diagnosis of PPE/PE:
• Chest pain, n (%) 29 (20) 21 (24) 8 (14) 1.9 (0.7–5.4) 0.212
• Sepsis, n (%) 32 (22) 10 (11) 22 (38) 0.2 (0.1–0.5) <0.001
Inflammatory parameters:
• WBC count (G/L), median (IQR) 15.1 (8.6–22.4) 15.8 (10.0–21.2) 13.6 (8.1–22.9) 0.636
• CRP (mg/L), median (IQR) 200 (157–317) 195 (152–314) 202 (160–318) 0.370
Pleural effusion characteristics
Pleural fluid:
• Gram stain positive, n (%) 32/125 (26) 14/81 (17) 18/44 (41) 0.3 (0.1–0.7) 0.002
• WBC count (cells/µl), median (IQR) 6604(1899–69,112)
4258
(1650–10,964)
71,000
(5900–121,980) <0.001
Size of effusion [5]:
• Grade 1 (small, < 14 hemithorax), n (%) 17/142 (12) 13/86 (15) 4/56 (7) 2.3 (0.7–10.2) 0.194• Grade 2 (moderate, 14 – 12 hemithorax), n (%) 35/142 (25) 30/86 (35) 5/56 (9) 5.4 (1.9–19.2) <0.001• Grade 3 (large, > 12 hemithorax), n (%) 90/142 (63) 43/86 (50) 47/56 (84) 0.2 (0.1–0.5) <0.001
Sonographic staging [8]:
• Stage 1 (exudative), n (%) 48/115 (42) 34/75 (45) 14/40 (35) 1.5 (0.7–3.7) 0.325
• Stage 2 (fibrino-purulent), n (%) 54/115 (47) 37/75 (49) 17/40 (43) 1.3 (0.6–3.1) 0.558
• Stage 3 (organized), n (%) 13/115 (11) 4/75 (5) 9/40 (23) 0.2 (0.1–0.8) 0.011
CRP, C-reactive protein; IQR, interquartile range; PE, pleural empyema; PPE, parapneumonic effusion; WBC, white
blood cell. Differences between PPE/PE patients without and with surgical intervention were determined by the
Mann-Whitney U test (medians) and Fisher’s exact test (proportions).
A pathogen was identified in 114 out of 147 (78%) children with PPE/PE and initial pleural tap
(Table 2). Pathogens were detected by conventional bacterial cultures of pleural fluid and/or blood in 48
(33%) patients. Antimicrobial treatment >24h prior to the diagnosis of PPE/PE was administered in 110
(75%) patients. The median treatment duration before sample collection was three days (IQR 1–5 days).
Negative pleural fluid cultures were more frequently observed when samples were collected >24 h
after initiation of antimicrobial treatment compared to those collected earlier (83% vs. 22%, p < 0.001).
Among patients with negative pleural fluid cultures (n = 99, 67%), PCR and antigen testing allowed to
identify a pathogen in two thirds of children (n = 66/99, 67%).
S. pneumoniae was detected in 90 (79%), S. pyogenes in 13 (11%) and Staphylococcus aureus in seven
(6%) cases. Other bacteria included non-typeable Haemophilus influenzae, Streptococcus intermedius,
Actinomyces spp., and Fusobacterium necrophorum. S. pneumoniae serotypes could be identified in 23 of
the 26 (88%) cultured bacterial isolates. The most common serotypes were serotype 3 (n = 7/23, 30%)
and serotype 19A (n = 5/23, 22%; Table 2). Infections with vaccine serotypes despite vaccination with
PCVs were observed in seven patients (serotype 3, n = 4; serotype 19A, 9V, and 1, n = 1).
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Table 2. Microbiological diagnosis in 114 out of the 147 children with PPE/PE.
Pathogen Detection (n = 114, 78%) Total Pleural Fluid PCR (n) Antigen (n)
Blood
n (%) Culture (n) Culture (n)
Streptococcus pneumoniae 90 (79) 13 a 39 84 b 16 a
Vaccine serotypes c:
1 4 2 2 4 2
3 7 3 1 4 5
7F 3 1 3 3
9V 1 1 1
19A 5 3 1 4 3
14 3 3 3
NA 3 3 2
Streptococcus pyogenes 13 (11) 12 d 2 e 1 4 d
Staphylococcus aureus 7 (6) 6 4
MSSA 6 5 f 4 f
MRSA 1 1 0
Others g 4 (4) 3 h 1 1
Total 114 34 42 85 25
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; PCR, polymerase chain reaction. a n = 3
with pleural fluid culture and blood culture positive; b n = 12 with antigen and pleural fluid culture positive,
n = 38 with antigen and PCR positive; c PCV7 (Prevenar 7®, introduced in 2006): serotypes 4, 6B, 9V, 14, 18C,
19F, 23F; PCV13 (Prevenar 13®, introduced in 2011): serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F;
d n = 4 with pleural fluid culture and blood culture positive; e n = 1 with PCR and antigen positive, n = 1 with
PCR and pleural fluid culture positive; f n = 3 with pleural fluid culture and blood culture positive; g non-typeable
Haemophilus influenzae (n = 1, pleural fluid culture and blood culture positive), Streptococcus intermedius (n = 2,
pleural fluid culture positive), Actinomyces spp. (n = 1, pleural fluid culture positive), and Fusobacterum necrophorum
(n = 1, detected by broad-range PCR); h n = 1 pleural fluid positive for both Actinomyces spp. and S. intermedius.
All cultured isolates (n = 48) were tested for antimicrobial susceptibility according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST) [14]. S. pyogenes and S. pneumoniae isolates were susceptible to
penicillin (minimum inhibitory concentration (MIC) for S. pneumoniae <0.06 mg/L, determined by Etest (AB Biodisk,
Solna, Sweden)) in 100% (n = 12/12) and 96% (n = 25/26), respectively. S. aureus isolates were susceptible to cefoxitin
(disk diameter ≥22 mm, determined by cefoxitin disk diffusion test) in 86% (n = 6/7). Children with these susceptible
isolates (n = 43) were treated with amoxicillin (AMX) with/without clavulanic acid (AMC), and the isolates were not
systematically tested against other antibiotics over the 15-year study period. This was also true for children with
other bacterial isolates (n = 3) that were all treated with AMX/AMC according to antimicrobial susceptibility testing.
One S. pneumoniae isolate was resistant against penicillin (MIC > 2 mg/L) and one MRSA was detected (cefoxitin
disk diameter <22 mm; in addition, detection of penicillin binding protein 2a (PBP2a) direct from S. aureus culture
isolate by the immunochromatographic assay Alere PBP2a Culture Colony Test (Alere, Scarborough, ME, USA)).
Their susceptibility testing results against other antibiotics were as follows: S. pneumoniae, clindamycin susceptible
(S), erythromycin S, vancomycin S; MRSA, clindamycin S, gentamicin S, vancomycin S, meropenem resistant (R).
Empirical treatment with AMX/AMC was initiated in all children at inclusion. AMX/AMC was
continued if pleural fluid and/or blood culture isolates were susceptible to this treatment (n = 46),
S. pneumoniae or S. pyogenes were identified by PCR and/or antigen testing (n = 66), or if no pathogen
was identified by bacterial cultures, PCR, or antigen testing (n = 33). All but two (n = 46/48, 96%)
culture isolates were susceptible to AMX/AMC. Resistant pathogens included penicillin-resistant
S. pneumoniae (n = 1) and methicillin-resistant S. aureus (MRSA, n = 1), both treated with vancomycin
based on antibiotic susceptibility testing. According to the management algorithm, 102 (69%) children
with PPE/PE received AMX/AMC treatment for a total duration of 14 days (Figure 1). Not managed
according to the management algorithm were PPE/PE patients receiving another antibiotic regimen
because of sepsis or adverse drug reactions (n = 22), or with a treatment duration >14 days because of
nosocomial infections apart from PPE/PE, including catheter-related bloodstream infections or skin
and soft tissue infections (n = 23).
Surgical interventions were performed in 58 (39%) children with PPE/PE, including chest tube
drainage alone (n = 36) or with intrapleural fibrinolytic therapy (n = 1), VATS (n = 16), and thoracotomy
(n = 5). Thereof, 27 (47%) children received a secondary intervention later than three days after diagnosis
of PPE/PE. Compared to PPE/PE patients without surgical intervention, patients that underwent surgical
intervention were more likely to have a positive pleural fluid Gram stain (p = 0.002), an increased
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white blood cell (WBC) count (p < 0.001), and a large size (p < 0.001) and organized (p = 0.011) effusion
(Table 1). The median LOS of all 147 children with PPE/PE was 11 days (IQR 8–19 days). PPE/PE
patients with surgical interventions were significantly longer hospitalized than those with pleural tap
alone (LOS 21 vs. 9 days, p < 0.001; Table 3).
Table 3. Management and outcome of the 147 children with PPE/PE.
Management
Total Number
of PPE/PE
Patients
(n = 147)
PPE/PE Patients
Without Surgical
Intervention
(n = 89, 61%)
PPE/PE Patients
with Surgical
Intervention
(n = 58, 39%)
OR
(95% CI) p Value
Hospitalization
LOS (days), median (IQR) 11 (8–19) 9 (6–13) 21 (12–34) <0.001
Antibiotic treatment
Duration (d) after time point of
diagnosis, median (range) 14 (2–255) 14 (4–20) 14 (2–255) 0.016
Total duration (d) including
pretreatment, median (range) 16 (13–255) 16 (14–30) 16 (13–255) 0.750
Outcome (n = 139) (n = 82, 59%) (n = 57, 41%)
Complete recovery, n (%) 134 (96) 80 (98) 54 (95) 2.2 (0.2–27.3) 0.401
Time to complete recovery
(months), median (IQR) 4.0 (3.6–5.1) 3.8 (3.5–4.7) 4.3 (3.7–6.0) 0.023
Complete recovery achieved in:
• ≤4 months FUP, n (%) 71 (51) 48 (59) 23 (41) 2.1 (1.0–4.4) 0.040
• 4–6 months FUP, n (%) 39 (28) 19 (23) 20 (35) 0.6 (0.3–1.3) 0.131
• >6 months FUP, n (%) 24 (17) 13 (16) 11 (19) 0.8 (0.3–2.1) 0.652
AMC, amoxicillin-clavulanate; AMX, amoxicillin; FUP, follow-up; IQR, interquartile range; LOS, length of hospital
stay; PE, pleural empyema; PPE, parapneumonic effusion. Complete recovery is defined as clinical and radiological
recovery. Differences between PPE/PE patients without and with surgical intervention were determined by the
Mann–Whitney U test (medians) and Fisher’s exact test (proportions).
Among 139 (95%) children with follow-up, complete clinical and radiological recovery occurred
in 134 (96%) patients. Thereof, 51% and 79% fully recovered until four and six months, respectively.
The median time to complete recovery was 4.0 months (range 0.5–12.8 months). Although the final
outcome was comparable between patients with surgical interventions and those with pleural tap
alone (complete recovery in 95% vs. 98%, p = 0.401), patients that underwent surgical intervention
needed significantly more time to recover (Figure 2A). Our final aim was to assess the outcome
of a management algorithm including diagnostic pleural tap and a 14-day course of AMX/AMC.
Two (2%) PPE/PE patients managed with the management algorithm and three (5%) with different
management experienced a poor outcome (p = 0.401). In fact, PPE/PE patients managed according to the
management algorithm recovered more rapidly than patients with a different management (Figure 2B).
The characteristics of the five (4%) PPE/PE patients with poor outcome, defined as incomplete clinical
and/or radiological recovery, are shown in Table 4. Thereof, only two (1%) suffered from clinical
impairment (chronic pneumopathy), while the three others reached complete clinical recovery.
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Figure 2. Outcome analysis of 139 children with parapneumonic effusion or pleural empyema (PPE/PE).
(A) Time to good outcome of PPE/PE with pleural tap alone (red) or surgical intervention (black)
(i.e., pleural draining catheter ± fibrinolysis, video-assisted thoracoscopic surgery, or thoracotomy).
(B) Time to good outcome of PPE/PE managed according to the study management algorithm (red) or
with different management (black). Poor outcome was defined as no clinical recovery and/or abnormal
chest radiograph according to the British Thoracic Society (BTS) guidelines [1]. The log-rank test was
used to compare the time to outcome.
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Table 4. Complications in children with PPE/PE.
Patient 1 2 3 4 5
Diagnosis PPE/PE PPE/PE with ARDS and DIC Necrotizing PPE/PE with MOF PPE/PE PPE/PE
Demographic characteristics
Sex Female Female Male Male Male
Age (y) 1 12 3 2 8
Previous medical history Recurrent viral bronchitis,trisomy 21 Recurrent viral bronchitis
Microbiology
Etiology S. pneumoniae(serotype unknown) MSSA MRSA
S. pneumoniae
(serotype 7F)
S. pneumoniae
(serotype 1)
Diagnostic test Antigen test (pleural fluid) Culture (blood) Culture (pleural fluid) Culture (blood, pleural fluid) Culture (blood), PCR and antigentest (pleural fluid)
Other detected pathogens NA Influenza B (NPS) Candida (CRBI) Influenza A (NPS) NA
Pleural effusion
Grading [5] 3 (large) 2 (moderate) 3 (large) 3 (large) 3 (large)
Staging [8] NA NA 1 (exudative) 2 (fibrino-purulent) 1 (exudative)
Hospitalization and management
LOS (days) 10 39 77 19 20
ICU (days) 15 55 5
Surgical intervention Pleural draining catheter Pleural draining catheter Thoracotomy and decortication following pleuraldraining catheter, VA-ECMO (9 days)
Complication Pneumothorax,bronchopleural fistula Pneumothorax, ARDS, DIC
Bronchopleural fistula, pneumothorax, necrotizing
pneumonia, MOF, ischemic cerebral lesions, CRBI
Antibiotics (total duration in days) AMC (14) AMX, gentamicin, flucloxacillin,clindamycin (21)
AMC, teicoplanin, gentamicin, meropenem,
vancomycin, linezolid (28) AMC (14) AMX (18)
FUP and outcome
Last FUP (months) 12 7 10 8 5
Clinical recovery + – + – +
Details NA Reduced lung function and exercise capacity NA Reduced lung function andexercise capacity NA
Radiological recovery – – – – –
Details Persistent bulla, residualpleural thickening Areas of air trapping Residual pleural thickening Emphysema, atelectasis Residual pleural thickening
AMC, amoxicillin-clavulanate; AMX, amoxicillin; ARDS, acute respiratory distress syndrome; CRBI, catheter-related bloodstream infection; DIC, disseminated intravascular coagulation;
FUP, follow-up; ICU, intensive care unit; LOS, length of hospital stay; MOF, multiple organ failure; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; NA,
not available; NPS, nasopharyngeal secretions; PE, pleural empyema; PPE, parapneumonic effusion; VA-ECMO, veno-arterial extracorporeal membrane oxygenation.
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4. Discussion
In this 15-year single-center cohort study in Switzerland, we showed that an initial tap-guided
management for children with PPE/PE including treatment with AMX/AMC for 14 days from pleural
tap resulted in full recovery in >95% of the cases. PPE/PE is a frequent complication of CAP for
which wide variations in management approaches exist [1–4,12,19–23]. We retrospectively analyzed
the feasibility and outcome following an uniform management algorithm for childhood PPE/PE that
included (I) enforced pathogen identification with initial diagnostic pleural tap, (II) 14-day-course of
antibiotics, i.e., AMX/AMC or targeted treatment according to microbiological test results, and (III)
surgical interventions restricted to cases with respiratory compromise, seropneumothorax, and/or large
effusions with mediastinal shift. Using this management algorithm, we corroborate previous findings
on the significantly increased percentage of pathogen identification in pleural fluid by extended
diagnostic techniques compared to the yield from blood cultures alone [13,24–29]. In our study, initial
pleural tap increased pathogen detection from 17% detection rate by blood cultures to 78% detection
rate by microbiological analyses of pleural fluid of PPE/PE patients. PCR and antigen testing enabled
pathogen detection in almost half of all patients that were already treated with antibiotics. Pleural tap
is a minimally invasive procedure with very rare complications [30] and sonographic guidance can
facilitate the procedure [23]. Our data support current guidelines in recommending a simple pleural
tap for children with PPE/PE, as it provides both diagnostic and therapeutic benefit [5,11]. Pleural tap
is a prerequisite for the narrow-spectrum antibiotic regimen of limited duration as suggested by our
management algorithm.
S. pneumoniae was the most frequently identified pathogen, followed by S. pyogenes and S. aureus,
which is in agreement with previously published data on the etiology of PPE/PE in children
worldwide [26,28,31–36]. The study period covered the introduction of PCVs in Switzerland among all
children <2 years of age (with a catch-up dose up to five years of age) with PCV7 in 2006 and a switch
to PCV13 in 2011 [17]. Infections with vaccine serotypes despite vaccination with PCVs occurred in
seven patients, mainly serotype 3, which is included in PCV13 [17]. Data on PCV coverage status in
our study is limited, and we thus cannot assess the influence of PCVs on pneumococcal PPE/PE in
this setting.
Our data confirm that empirical antibiotic treatment must target S. pneumoniae and cover S. pyogenes
and S. aureus [11,28,35]. The choice of the empirical antibiotic agent should be guided by local resistance
data and the emergence of resistant organisms [11]. AMX/AMC is one recommended suitable option
for PPE/PE following CAP according to current guidelines [1,5,11,37]. AMC can be narrowed to AMX
in case of S. pneumoniae and S. pyogenes detection [5]. In fact, 46 out of 48 (96%) cultured pathogens
in this study were susceptible to treatment with AMX/AMC. Notably, pleural tap allowed also the
detection of Actinomyces spp. in pleural fluid culture of one patient, which required AMC treatment
for a prolonged duration of six months. The two (4%) AMX/AMC-resistant pathogens isolated from
pleural fluid were penicillin-resistant S. pneumoniae and MRSA, respectively. However, the prevalence
of penicillin-resistant S. pneumoniae [38] and MRSA [39] is still very low in Switzerland and may
not justify an antibiotic escalation regimen for the empirical treatment of PPE/PE. Even less if the
management includes an initial diagnostic pleural tap to identify pathogens that are resistant against
the empirical treatment. The pleural tap-guided management will allow correct and targeted antibiotic
treatment of limited duration that prevents further emergence of resistant pathogens.
No evidence exists about the duration of antibiotic treatment for PPE/PE [11,37,40]. Intravenous
antibiotic treatment is usually continued until there is obvious clinical improvement, and subsequent
oral antibiotic treatment such as AMX/AMC is administered for 1–4 weeks following discharge [37,40].
In this study, we showed that treatment with AMX/AMC restricted to total 14 days following pleural tap
led to good outcome in the vast majority of cases (98%), independent of a management with tap-guided
antibiotic treatment alone or with surgical intervention. Notably, PPE/PE patients show variable
disease courses with sometimes very protracted recovery due to pronounced inflammatory processes
within the pleural cavity, even after successful killing of organisms at the local site. This may have led
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to the varying recommendations for extensive treatment durations in children with PPE/PE [11,13,40].
However, the median length of treatment in our study was 14 days for all antibiotic regimens and
irrespective of interventions, and we thus propose to limit treatment duration for this condition to a
total of two weeks following diagnosis.
The indication for and role of surgical interventions in the management of childhood PPE/PE
is controversial [20,37,41]. Because fibrin formation impairs drainage of pleural fluid, surgical
interventions are recommended for PPE/PE patients in which pleural fluid has already progressed to
an effusion with multiple loculations [10]. It has been suggested that pleural draining catheter with
fibrinolysis may be a preferred primary therapy in empyema and that VATS should be reserved for
failure of initial management with antibiotics alone [37]. However, recent studies reported a successful
management without surgical intervention in a considerable number of PPE/PE patients even with
effusions loculated by fibrous septations and consolidations [9,41]. In line with these data, our study
demonstrates that PPE/PE could be managed with a simple diagnostic pleural tap without surgical
interventions in 61% of all cases, half of which had a large size of effusion. Surgical interventions were
restricted to cases with a high degree of respiratory compromise, seropneumothorax, and/or large
effusions causing mediastinal shift. There was no difference in outcome of children with different
methods of surgical interventions (data not shown). The overall median LOS in our study with
11 days was significantly shorter compared to other European studies (Germany, 17 days [12]; Poland,
20 days [36]; Spain, 17 days [42]; and Israel, 15 days [43]). In contrast to other studies [12,44], our PPE/PE
patients with surgical interventions were significantly longer hospitalized than those with pleural
tap alone, and required significantly longer time to full recovery. Overall, the full recovery in 96% of
children with PPE/PE further suggests that the presented management algorithm may be indeed a safe
and minimal-invasive approach to manage PPE/PE in children with a rational and targeted antibiotic
regimen following pleural tap.
The strengths of this study are the long observational period and the single-center design,
which enabled us to implement and standardize a uniform management algorithm and closely follow
a well-defined study cohort. However, the study also has several limitations. First, our center is a large
tertiary university hospital and many patients were already pretreated and secondarily referred by
primary physicians or secondary centers. Second, due to the retrospective study design we are unable to
provide information on total numbers of cases with CAP, PPE/PE following CAP who did not undergo
a pleural tap procedure, and PPE/PE in children with underlying diseases or immunosuppression.
Third, as previously mentioned [3], surgical interventions are reflected by the current skills and
experience of treating surgeons and pediatricians. However, apart from performing VATS instead of
thoracotomy because of several evidence-based advantages [20,37], no major intervention changes
were introduced during the study period. Finally, although PCR and antigen testing substantially
enabled increased pathogen detection, pleural fluid was not in all cases investigated by both PCR and
antigen testing techniques.
5. Conclusions
The outcomes of this study strongly suggest that a standardized management of PPE/PE in
children, including an initial diagnostic pleural tap and consistent prescription of a two-week-course
of antibiotic treatment adjusted to microbiological test results, is effective and safe in most children.
This finding is consistent with studies that have been done previously. The empirical treatment
regimen including monotherapy with AMX/AMC can be adapted in countries with low prevalence of
penicillin-resistant S. pneumoniae and MRSA, and AMC can be narrowed to AMX in case of S. pneumoniae
and S. pyogenes detection in this setting. Surgical interventions may be restricted to cases with a high
degree of respiratory compromise, seropneumothorax, and/or large effusions causing mediastinal shift.
Although children with PPE/PE show variable disease courses with protracted recovery the overall
prognosis of pediatric PPE/PE is good. Our pleural tap-guided treatment resulted in full recovery in
over 95% of children with PPE/PE, irrespective of the management with pleural tap alone or surgical
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interventions. A prospective multicenter study is needed in the future to verify these single center
findings within the pediatric population.
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